2023-12-04 カーディフ大学
◆この研究では、アスピリンががん治療に与える影響を評価するため、約100万人のがん患者を対象にした118の観察研究の結果を調査しました。その結果、アスピリンの低用量摂取(1日75または81 mg)は、がん死亡率と全死亡原因からの死亡率の両方で20%の低減と関連していることが示されました。
◆アスピリンはがんの生物学的メカニズムをターゲットにし、転移性がんの拡散とがん患者の血管合併症のリスクを減少させるとされています。研究者は、アスピリンの利用は相対的に安全であるため、がん治療の一環として積極的に推奨すべきだと結論づけています。
<関連情報>
- https://www.cardiff.ac.uk/news/view/2782804-aspirin-and-treating-cancer
- https://www.nature.com/articles/s41416-023-02506-5
アスピリンと癌治療:証拠の系統的レビューとメタ分析:賛成と反対 Aspirin and cancer treatment: systematic reviews and meta-analyses of evidence: for and against
Peter Elwood,Gareth Morgan,John Watkins,Majd Protty,Malcolm Mason,Richard Adams,Sunil Dolwani,Janet Pickering,Christine Delon & Marcus Longley
British Journal of Cancer Published:29 November 2023
DOI:https://doi.org/10.1038/s41416-023-02506-5
Abstract
Aspirin as a possible treatment of cancer has been of increasing interest for over 50 years, but the balance of the risks and benefits remains a point of contention. We summarise the valid published evidence ‘for’ and ‘against’ the use of aspirin as a cancer treatment and we present what we believe are relevant ethical implications. Reasons for aspirin include the benefits of aspirin taken by patients with cancer upon relevant biological cancer mechanisms. These explain the observed reductions in metastatic cancer and vascular complications in cancer patients. Meta-analyses of 118 observational studies of mortality in cancer patients give evidence consistent with reductions of about 20% in mortality associated with aspirin use. Reasons against aspirin use include increased risk of a gastrointestinal bleed though there appears to be no valid evidence that aspirin is responsible for fatal gastrointestinal bleeding. Few trials have been reported and there are inconsistencies in the results. In conclusion, given the relative safety and the favourable effects of aspirin, its use in cancer seems justified, and ethical implications of this imply that cancer patients should be informed of the present evidence and encouraged to raise the topic with their healthcare team.
